Philip P.C. Ip
YOU?
Author Swipe
View article: P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis
P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis Open
View article: CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study Open
View article: Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features
Malignant ascites in ovarian cancer is compatible with long-term (10 year) survival with associations to clinicopathological features Open
View article: Oncocytes in Thyroid Aspirates—Implications of Clinical Parameters and Cytologic Diagnosis
Oncocytes in Thyroid Aspirates—Implications of Clinical Parameters and Cytologic Diagnosis Open
Importance The clinical significance of oncocytes in thyroid aspirate is uncertain, leading to inconsistent and possible over-treatment. Objective To determine the predictive significance of clinico-radiological parameters and cytologic di…
View article: Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis
Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis Open
View article: Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis
Bola-Amphiphilic Dendrimer Enhances Imatinib to Target Metastatic Ovarian Cancer via β-Catenin-HRP2 Signaling Axis Open
Ovarian cancer is the leading cause of death among all gynecological malignancies, and drug resistance renders the current chemotherapy agents ineffective for patients with advanced metastatic tumors. We report an effective treatment strat…
View article: P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis
P-cadherin mechanoactivates tumor-mesothelium metabolic coupling to promote ovarian cancer metastasis Open
View article: Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S3. Autopsy findings on a representative mouse treated with 7.5 mg/kg CFI-400945 (hematoxylin and eosin staining).
View article: Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S2. DNA content and centrosome number quantification in myogenic sarcoma cell lines after CFI-400945 treatment.
View article: Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S2 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S2. DNA content and centrosome number quantification in myogenic sarcoma cell lines after CFI-400945 treatment.
View article: Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S5. Oncoplot of key genes responsible for DNA repair among sarcoma cell lines.
View article: Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Data S1. Small variants, copy number alterations, structural variants, and fusion transcripts of DNA repair genes.
View article: Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S1. Sanger sequencing of SK-UT-1 and SKN BRAC2-KO.
View article: Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose:Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA d…
View article: Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Data S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Data S1. Small variants, copy number alterations, structural variants, and fusion transcripts of DNA repair genes.
View article: Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S6. Genomic alterations involving key genes responsible for DNA repair in uterine leiomyosarcoma.
View article: Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S5 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S5. Oncoplot of key genes responsible for DNA repair among sarcoma cell lines.
View article: Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Table S1. Clinicopathologic features of 25 uterine leiomyosarcoma.
View article: Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S3. Autopsy findings on a representative mouse treated with 7.5 mg/kg CFI-400945 (hematoxylin and eosin staining).
View article: Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S1. Sanger sequencing of SK-UT-1 and SKN BRAC2-KO.
View article: Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S6 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S6. Genomic alterations involving key genes responsible for DNA repair in uterine leiomyosarcoma.
View article: Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Data from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose:Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA d…
View article: Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Table S1 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Table S1. Clinicopathologic features of 25 uterine leiomyosarcoma.
View article: Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S4. Autopsy findings on two mice from two different 5 mg/kg CFI-400945 treatment groups that were withdrawn from the experiments (hematoxylin and eosin staining).
View article: Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Supplementary Figure S4 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Supplementary Figure S4. Autopsy findings on two mice from two different 5 mg/kg CFI-400945 treatment groups that were withdrawn from the experiments (hematoxylin and eosin staining).
View article: Bola-amphiphilic dendrimer empowers imatinib to target metastatic ovarian cancer stem cells<i>via</i>β-catenin-HRP2 signaling axis
Bola-amphiphilic dendrimer empowers imatinib to target metastatic ovarian cancer stem cells<i>via</i>β-catenin-HRP2 signaling axis Open
Ovarian cancer is the leading cause of death among all gynecological malignancies, and drug resistance renders the current chemotherapy agents ineffective for patients with advanced metastatic tumors. We report an effective treatment strat…
View article: Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma Open
Purpose: Uterine leiomyosarcoma (LMS) is an aggressive sarcoma and a subset of which exhibits DNA repair defects. Polo-like kinase 4 (PLK4) precisely modulates mitosis, and its inhibition causes chromosome missegregation and increased DNA …
View article: P-cadherin mechanoactivates tumor–mesothelium metabolic coupling to promote ovarian cancer metastasis
P-cadherin mechanoactivates tumor–mesothelium metabolic coupling to promote ovarian cancer metastasis Open
Peritoneal metastasis exacerbates the prognosis of ovarian cancer patients. Adhesion of cancer cells to mesothelium is a rate-limiting prerequisite for this process. How metastatic cells sense and respond to the dynamic biomechanical micro…
View article: Prospective validation of the role of PET/CT in detecting disease after neoadjuvant chemotherapy in advanced ovarian cancer
Prospective validation of the role of PET/CT in detecting disease after neoadjuvant chemotherapy in advanced ovarian cancer Open
View article: Supplementary Figure S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Supplementary Figure S1 from Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas Open
Representative relative copy number plots.